Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185


An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.

Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ.

J Lipid Res. 2005 May;46(5):872-84. Epub 2005 Feb 16.


Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, Levin AA, Geary RS.

Biochem Pharmacol. 2009 Mar 1;77(5):910-9. doi: 10.1016/j.bcp.2008.11.005. Epub 2008 Nov 14.


Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms.

Srivastava RA, Averna M, Srivastava N, Pape ME.

Int J Biochem Cell Biol. 2001 Dec;33(12):1215-26.


Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

Mullick AE, Fu W, Graham MJ, Lee RG, Witchell D, Bell TA, Whipple CP, Crooke RM.

J Lipid Res. 2011 May;52(5):885-96. doi: 10.1194/jlr.M011791. Epub 2011 Feb 22.


Liver LDL receptor mRNA expression is decreased in human ApoB/CETP double transgenic mice and is regulated by diet as well as the cytokine oncostatin M.

Liu J, Zhang YL, Spence MJ, Vestal RE, Wallace PM, Grass DS.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2948-54.


Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.

Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ, Kelly S, Chen S, McKay R, Monia BP, Bhanot S.

Hepatology. 2005 Aug;42(2):362-71.


Hepatic lipase overexpression lowers remnant and LDL levels by a noncatalytic mechanism in LDL receptor-deficient mice.

Dichek HL, Johnson SM, Akeefe H, Lo GT, Sage E, Yap CE, Mahley RW.

J Lipid Res. 2001 Feb;42(2):201-10.


Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization.

Alger HM, Brown JM, Sawyer JK, Kelley KL, Shah R, Wilson MD, Willingham MC, Rudel LL.

J Biol Chem. 2010 May 7;285(19):14267-74. doi: 10.1074/jbc.M110.118422. Epub 2010 Mar 15.


PPARalpha deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins.

Lindén D, Alsterholm M, Wennbo H, Oscarsson J.

J Lipid Res. 2001 Nov;42(11):1831-40.


Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor-knockout mice by adenovirus-mediated gene delivery of ApoB mRNA editing enzyme (Apobec1).

Teng B, Ishida B, Forte TM, Blumenthal S, Song LZ, Gotto AM Jr, Chan L.

Arterioscler Thromb Vasc Biol. 1997 May;17(5):889-97.


Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.

Thomas T, Ginsberg H.

Curr Atheroscler Rep. 2010 Jan;12(1):58-65. doi: 10.1007/s11883-009-0078-7. Review.


Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.

Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S.

Circulation. 2008 Aug 12;118(7):743-53. doi: 10.1161/CIRCULATIONAHA.108.786822. Epub 2008 Jul 28.


Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM.

Circulation. 2006 Oct 17;114(16):1729-35. Epub 2006 Oct 9.


Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.

Lee RG, Fu W, Graham MJ, Mullick AE, Sipe D, Gattis D, Bell TA, Booten S, Crooke RM.

J Lipid Res. 2013 Mar;54(3):602-14. doi: 10.1194/jlr.M029215. Epub 2012 Dec 6.

Items per page

Supplemental Content

Write to the Help Desk